Drug Trial Radar · NCT00660504
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Apr 2008
Primary completion
Feb 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.
Conditions
- Lung Cancer
Interventions
Amrubicin HydrochlorideDrug
Amrubicin Hydrochloride combined with cisplatin
Etoposide-Cisplatin combined chemotherapyDrug
combined chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 1.5 years after last subject enrolled
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Tianjin, China
Site not named
Fuzhou, Fujian, China
Site not named
Lanzhou, Gansu, China
Site not named
Guangzhou, Guangdong, China
Site not named
Changsha, Hunan, China
Site not named
Nanjing, Jiangsu, China
Site not named
Nanchang, Jiangxi, China
Site not named
Changchun, Jilin, China
Site not named
Dalian/Shenyang, Liaoning, China
Site not named
Shenyang, Liaoning, China
Site not named
Xian, Shanxi, China
Site not named
Chengdu, Sichuan, China
Site not named
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.